Back to search
FDAFDA · Food and drugs·Recall number D-822-2013

Enablex (darifenacin) Extended Release Tablet, 15 mg per tablet. Physician Sample 7 Tablets bottle, Rx only, Mfd by: Novartis Pharma Stein AG, Stein, Switzerland, NDC 0078-9420-07

Published August 7, 2013 · Recall initiated: May 17, 2013

Summary

FDA records drug Class II recall D-822-2013, published August 7, 2013 and initiated May 17, 2013. Recalling firm: Warner Chilcott US LLC; Status: Terminated; Reported quantity: 188,600 bottles; Lot: Lot F1002 - Exp.12/13. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: unspecified degradation product

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Warner Chilcott US LLC
Distributor
Nationwide
Lot
Lot F1002 - Exp.12/13
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Enablex (darifenacin) Extended Release Tablet, 15 mg per tablet. Physician Sample 7 Tablets bottle, Rx only, Mfd by: Novartis Pharma Stein AG, Stein, Switzerland, NDC 0078-9420-07 recalled?

Yes. FDA published recall D-822-2013 on August 7, 2013. Reported hazard: Failed Impurities/Degradation Specifications: unspecified degradation product

What should I do if I have this product?

Voluntary: Firm initiated · Letter